

---

<b>Product Name</b>	: AXT107	LRRFSTAPFAFI-DINDVINF
<b>Cat. No.</b>	: PC-72429	
<b>CAS No.</b>	: 2417491-82-6	
<b>Molecular Formula</b>	: C <sub>111</sub> H <sub>167</sub> N <sub>29</sub> O <sub>28</sub>	
<b>Molecular Weight</b>	: 2355.69	
<b>Target</b>	: Integrin	
<b>Solubility</b>	: 10 mM in H <sub>2</sub> O	

### Biological Activity

AXT107 (Gersizangitide) is a mimetic peptide derived from collagen IV, binds **integrins  $\alpha v\beta 3$**  and  **$\alpha 5\beta 1$**  (K<sub>d</sub>=1.29 and 2.21 nM), disrupts VEGFR2- $\beta 3$  complex formation.

AXT107 inhibits VEGF-, HGF-, and PDGF-BB-stimulated phosphorylation of VEGFR2, c-Met, and PDGFRb receptors.

AXT107 also reduced total VEGFR2 levels by increasing internalization, ubiquitination, and degradation.

AXT107 suppressed subretinal neovascularization (NV) in two mouse models predictive of effects in neovascular age-related macular degeneration (NVAMD) and inhibited retinal NV in a model predictive of effects in ischemic retinopathies.

A combination of AXT107 and the current treatment aflibercept suppressed subretinal NV better than either agent alone.

AXT107 significantly reduced VEGF-induced vascular leakage by 86% at 1 month and 70% at 2 months in rabbit eyes, demonstrating the longer effectiveness than Aflibercept.

### References

Raquel Lima E Silva, et al. *Sci Transl Med*. 2017 Jan 18;9(373):eaai8030.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com

---